CTKB

$4.25

Post-MarketAs of Mar 17, 8:00 PM UTC

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$4.25
Potential Upside
5%
Whystock Fair Value$4.46
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryMedical Devices

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora ...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$546.34M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.31
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-18.05%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
4.29

Recent News

MarketBeat
Mar 9, 2026

Cytek Biosciences Highlights Aurora Evo, Recurring Revenue Growth and 2026 Outlook at TD Cowen Conference

Cytek Biosciences (NASDAQ:CTKB) outlined its recent product launches, geographic diversification, and expectations for 2026 during a presentation and fireside chat at TD Cowen’s 42nd annual healthcare conference. CEO and Chairman Wenbin Jiang and CFO William McCombe discussed the company’s installed

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Mar 9, 2026

How The Cytek Biosciences (CTKB) Story Is Shifting With New Targets And 2026 Guidance

Cytek Biosciences has seen its fair value estimate adjusted from US$5.75 to US$6.00, placing the stock in a slightly higher US$5 to US$6 price target framework. Analysts attribute this shift to a more constructive stance on the name, using clearer multi year models and a potential recovery in diagnostic tools to outline where Cytek could sit within the group. As you read on, you will see how these evolving targets and narratives might influence the way you track the story from here. Analyst...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Motley Fool
Feb 27, 2026

Cytek (CTKB) Q4 2025 Earnings Call Transcript

At this time, I would like to welcome everyone to the Cytek Biosciences, Inc. fourth quarter 2025 earnings call. Earlier today, Cytek Biosciences, Inc. released financial results for the fourth quarter and year ended 12/31/2025. A copy of the news release is also available on the Investor Relations section of the Cytek Biosciences, Inc. website at investors.cytekbio.com.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Moby
Feb 27, 2026

Cytek Biosciences, Inc. Q4 2025 Earnings Call Summary

Moby summary of Cytek Biosciences, Inc.'s Q4 2025 earnings call

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
GuruFocus.com
Feb 27, 2026

Cytek Biosciences Inc (CTKB) Q4 2025 Earnings Call Highlights: Record Revenue Amidst Challenges

Despite achieving record revenue, Cytek Biosciences Inc (CTKB) faces profitability pressures due to increased costs and a net loss in Q4 2025.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.